Provide feedbackProvide feedback

Home :: Hematology/Oncology :: Prostate Cancer

MDxHealth signs agreement with Prime Health Services to provide greater access to prostate cancer test

Tuesday, March 04 2014 | Comments
Evidence Grade 0 What's This?

MDxHealth SA, a Belgian molecular diagnostic company, signed an agreement with Prime Health Services Inc., a national medical cost-containment company that includes a preferred provider organization network, to offer patients greater access to MDxHealth's ConfirmMDx for prostate cancer test. The agreement will extend the access to the test to Prime Health's 144 million members in all 50 states. According to MDxHealth, its test reduces the number of false negative prostate biopsy...

MDxHealth SA, a Belgian molecular diagnostic company, signed an agreement with Prime Health Services Inc., a national medical cost-containment company that includes a preferred provider organization network, to offer patients greater access to MDxHealth's ConfirmMDx for prostate cancer test.

The agreement will extend the access to the test to Prime Health's 144 million members in all 50 states.

According to MDxHealth, its test reduces the number of false negative prostate biopsy results, which are seen in approximately 25 percent to 35 percent of the nearly 1 million men with a negative prostate cancer biopsy each year.

The company said agreements such this one will shorten its reimbursement cycle and increase revenue for this year.

Latest News

Higher levels of melatonin may decrease prostate cancer risk, study shows Verusmed

Wednesday, February 05 2014 | Comments
Evidence Grade 0 What's This?

Men with higher levels of melatonin, a hormone involved in the sleep-wake cycle, appear to have a decreased risk for advanced prostate cancer, according to results presented in San Diego at the American Association for Cancer Research (AACR)-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research.

Researchers conducted a case-cohort study of 928 Icelandic men to...

Tags: Prostate Cancer


FDA lifts clinical hold on GTx's trials of Capesaris in advanced prostate cancer Verusmed

Tuesday, May 08 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration removed its full clinical hold on GTx Inc.'s Investigational New Drug (IND) application for Capesaris, a selective estrogen receptor alpha agonist that GTx is developing as a treatment for advanced prostate cancer.

The FDA issued the hold on clinical trials of the drug in February after GTx reported an...

Tags: Prostate Cancer, Prostate Cancer


FDA rejects Amgen's Xgeva sBLA for prevention of bone metastases Verusmed

Friday, April 27 2012 | Comments
Evidence Grade 0 What's This?

Amgen Inc. received a complete response letter from the Food and Drug Administration regarding the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to treat men with castration-resistant prostate cancer who are at high risk for developing bone metastases. 

The FDA said it could not approve the application in its present form. According to...

Tags: Prostate Cancer, Prostate Cancer


Ezose Sciences to collaborate with Hirosaki University to identify new cancer biomarkers Verusmed

Monday, April 23 2012 | Comments
Evidence Grade 0 What's This?

Ezose Sciences Inc. established a research collaboration with Hirosaki University to identify new biomarkers that could help predict and monitor the progression of prostate cancer and other urologic cancers.

Hirosaki University investigators will collect serum and urine samples from well-characterized patient and control populations in Japan. Ezose will analyze the samples using its...

Tags: Prostate Cancer, Prostate Cancer




Hematology/Oncology Conference Coverage
  1. No articles have been read
  1. No articles have been emailed
Videos